Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 3 , Pages 147-156 , March 2010

Metabolic toxicity of the heart: Insights from molecular imaging

  • P. Iozzo

      Affiliations

    • Corresponding Author InformationTel.: +39 050 315 3525; fax: +39 050 315 2166.

Received 5 March 2009 ,Accepted 21 August 2009.

References 

  1. Schelbert HR. Coronary circulatory function abnormalities in insulin resistance. Insights from positron emission tomography. J Am Coll Cardiol. 2009;53:S3–S8
  2. Iozzo P, Chareonthaitawee P, Di Terlizzi M, Betteridge DJ, Ferrannini E, Camici PG. Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab. 2002;282:E1163–E1171
  3. Knaapen P, Germans T, Knuuti J, Paulus WJ, Dijkmans PA, Allaart CP, et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation. 2007;115:918–927
  4. Kates AM, Herrero P, Dence C, Soto P, Srinivasan M, Delano DG, et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol. 2003;41:293–299
  5. Kankaanpää M, Lehto HR, Pärkkä JP, Komu M, Viljanen A, Ferrannini E, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab. 2006;91:4689–4695
  6. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49:417–423
  7. Okada M, Mitsunami K, Inubushi T, Kinoshita M. Influence of aging or left ventricular hypertrophy on the human heart: contents of phosphorus metabolites measured by 31P MRS. Magn Reson Med. 1998;39:772–782
  8. Nakae I, Mitsunami K, Matsuo S, Matsumoto T, Morikawa S, Inubushi T, et al. Assessment of myocardial creatine concentration in dysfunctional human heart by proton magnetic resonance spectroscopy. Magn Reson Med Sci. 2004;3:19–25
  9. Tuunanen H, Engblom E, Naum A, Någren K, Hesse B, Airaksinen KE, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 2006;114:2130–2137
  10. Sundell J, Nuutila P, Laine H, Luotolahti M, Kalliokoski K, Raitakari O, et al. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes. 2002;51:1125–1130
  11. Choi Y, Brunken RC, Hawkins RA, Huang SC, Buxton DB, Hoh CK, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-d-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med. 1993;20:308–318
  12. Nuutila P, Knuuti MJ, Raitakari M, Ruotsalainen U, Teräs M, Voipio-Pulkki LM, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Phys. 1994;267:E941–E946
  13. Takala TO, Nuutila P, Katoh C, Luotolahti M, Bergman J, Mäki M, et al. Myocardial blood flow, oxygen consumption, and fatty acid uptake in endurance athletes during insulin stimulation. Am J Physiol. 1999;277:E585–E590
  14. Slot JW, Geuze HJ, Gigengack S, James DE, Lienhard GE. Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad Sci U S A. 1991;88:7815–7819
  15. Peterson LR, Herrero P, McGill J, Schechtman KB, Kisrieva-Ware Z, Lesniak D, et al. Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes. 2008;57:32–40
  16. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teräs M, Haaparanta M, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest. 1992;89:1767–1774
  17. Reingold JS, McGavock JM, Kaka S, Tillery T, Victor RG, Szczepaniak LS. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab. 2005;289:E935–E939
  18. Hammer S, van der Meer RW, Lamb HJ, Schär M, de Roos A, Smit JW, et al. Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men. J Clin Endocrinol Metab. 2008;93:497–503
  19. van der Meer RW, Hammer S, Lamb HJ, Frölich M, Diamant M, Rijzewijk LJ, et al. Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men. J Clin Endocrinol Metab. 2008;93:2702–2708
  20. Chareonthaitawee P, Kaufmann PA, Rimoldi O, Camici PG. Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. Cardiovasc Res. 2001;50:151–161
  21. Herrero P, Soto PF, Dence CS, Kisrieva-Ware Z, Delano DA, Peterson LR, et al. Impact of hormone replacement on myocardial fatty acid metabolism: potential role of estrogen. J Nucl Cardiol. 2005;12:574–581
  22. Peterson LR, Soto PF, Herrero P, Schechtman KB, Dence C, Gropler RJ. Sex differences in myocardial oxygen and glucose metabolism. J Nucl Cardiol. 2007;14:573–581
  23. Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging. 2008;1:424–433
  24. Nuutila P, Knuuti MJ, Mäki M, Laine H, Ruotsalainen U, Teräs M, et al. Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes. 1995;44:31–36
  25. Köstler H, Landschütz W, Koeppe S, Seyfarth T, Lipke C, Sandstede J, et al. Age and gender dependence of human cardiac phosphorus metabolites determined by SLOOP 31P MR spectroscopy. Magn Reson Med. 2006;56:907–911
  26. Duvernoy CS, Rattenhuber J, Seifert-Klauss V, Bengel F, Meyer C, Schwaiger M. Myocardial blood flow and flow reserve in response to short-term cyclical hormone replacement therapy in postmenopausal women. J Gend Specif Med. 2001;4:21–27
  27. Peterson LR, Eyster D, Dávila-Román VG, Stephens AL, Schechtman KB, Herrero P, et al. Short-term oral estrogen replacement therapy does not augment endothelium-independent myocardial perfusion in postmenopausal women. Am Heart J. 2001;142:641–647
  28. Uren NG, Camici PG, Melin JA, Bol A, de Bruyne B, Radvan J, et al. Effect of aging on myocardial perfusion riserve. J Nucl Med. 1995;36:2032–2036
  29. Kates AM, Herrero P, Dence C, Soto P, Srinivasan M, Delano DG, et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol. 2003;41:293–299
  30. van der Meer RW, Rijzewijk LJ, Diamant M, Hammer S, Schär M, Bax JJ, et al. The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J. 2008;29:1516–1522
  31. Schocke MF, Metzler B, Wolf C, Steinboeck P, Kremser C, Pachinger O, et al. Impact of aging on cardiac high-energy phosphate metabolism determined by phosphorus-31 2-dimensional chemical shift imaging (31P 2D CSI). Magn Reson Imaging. 2003;21:553–559
  32. Standl E, Schnell O. A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia. 2000;43:1455–1469
  33. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–313
  34. Sundell J, Laine H, Nuutila P, Rönnemaa T, Luotolahti M, Raitakari O, et al. The effects of insulin and short-term hyperglycaemia on myocardial blood flow in young men with uncomplicated Type I diabetes. Diabetologia. 2002;45:775–782
  35. Iozzo P, Chareonthaitawee P, Rimoldi O, Betteridge DJ, Camici PG, Ferrannini E. Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes. Diabetologia. 2002;45:1404–1409
  36. Søndergaard HM, Bøttcher M, Marie Madsen M, Schmitz O, Hansen SB, Nielsen TT, et al. Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease. J Clin Endocrinol Metab. 2006;91:4854–4861
  37. Lautamäki R, Airaksinen KE, Seppänen M, Toikka J, Härkönen R, Luotolahti M, et al. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease. Diabetes. 2006;55:511–516
  38. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes. 2002;51:3020–3024
  39. vom Dahl J, Herman WH, Hicks RJ, Ortiz-Alonso FJ, Lee KS, Allman KC, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation. 1993;88:395–404
  40. Dutka DP, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS, et al. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol. 2006;48:2225–2231
  41. Utriainen T, Takala T, Luotolahti M, Rönnemaa T, Laine H, Ruotsalainen U, et al. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia. 1998;41:555–559
  42. Knuuti J, Takala TO, Någren K, Sipilä H, Turpeinen AK, Uusitupa MI, et al. Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia. 2001;44:184–187
  43. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109:2191–2196
  44. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170–1175
  45. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793–1799
  46. Perseghin G, Ntali G, De Cobelli F, Lattuada G, Esposito A, Belloni E, et al. Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance. Diabetes Care. 2007;30:1520–1526
  47. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040–3046
  48. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003;42:328–335
  49. Metzler B, Schocke MF, Steinboeck P, Wolf C, Judmaier W, Lechleitner M, et al. Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson. 2002;4:493–502
  50. Hammer S, van der Meer RW, Lamb HJ, de Boer HH, Bax JJ, de Roos A, et al. Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2008;295:E714–E718
  51. Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, Pijl H, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol. 2008;52:1006–1012
  52. Viljanen APM, Karmi A, Borra R, Pärkkä JP, Lepomäki V, Parkkola R, et al. Effect of caloric restriction on myocardial fatty acid uptake, left ventricular mass and cardiac work in obese adults. Am J Cardiol. 2009;103:1721–1726
  53. Hällsten K, Virtanen KA, Lönnqvist F, Janatuinen T, Turiceanu M, Rönnemaa T, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med. 2004;21:1280–1287
  54. Lautamäki R, Airaksinen KE, Seppänen M, Toikka J, Luotolahti M, Ball E, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes. 2005;54:2787–2794
  55. van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119:2069–2077
  56. Zib I, Jacob AN, Lingvay I, Salinas K, McGavock JM, Raskin P, et al. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med. 2007;55:230–236
  57. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation. 2009;119:2568–2577
  58. Katz AM. Heart failure: pathophysiology, molecular biology, and clinical management. Philadelphia, PA: Lippincott Williams & Wilkins; 2000;
  59. Mohan SB, Parker M, Wehbi M, Douglass P. Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure. Cleve Clin J Med. 2002;69:481–487
  60. Tamaki N, Magata Y, Takahashi N, Kawamoto M, Torizuka T, Yonekura Y, et al. Myocardial oxidative metabolism in normal subjects in fasting, glucose loading and dobutamine infusion states. Ann Nucl Med. 1992;6:221–228
  61. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest. 1996;98:2094–2099
  62. Di Carli M, Czernin J, Hoh CK, Gerbaudo VH, Brunken RC, Huang SC, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 1995;91:1944–1951
  63. Mäki MT, Haaparanta M, Nuutila P, Oikonen V, Luotolahti M, Eskola O, et al. Free fatty acid uptake in the myocardium and skeletal muscle using fluorine-18-fluoro-6-thia-heptadecanoic acid. J Nucl Med. 1998;39:1320–1327
  64. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. J Nucl Med. 2001;42:55–62
  65. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, et al. The creatine kinase system in normal and diseased human myocardium. N Engl J Med. 1985;313:1050–1054
  66. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190–2196
  67. Tian R, Ingwall JS. Energetic basis for reduced contractile reserve in isolated rat hearts. Am J Physiol. 1996;270:H1207–H1216
  68. Spindler M, Engelhardt S, Niebler R, Wagner H, Hein H, Lohse MJ, et al. Alterations in the myocardial creatine kinase system precede the development of contractile dysfunction in β1-adrenergic receptor transgenic mice. J Mol Cell Cardiol. 2003;35:389–397
  69. Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamoto T, Matsuo S, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol. 2003;42:1587–1593
  70. Vogt M, Motz WH, Schwartzkopf B, Strauer BE. Pathophysiology and clinical aspects of hypertensive hypertrophy. Eur Heart J. 1993;14(Suppl. D):2–7
  71. Katz AM. Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. J Cell Mol Med. 2003;7:1–10
  72. Laine H, Katoh C, Luotolahti M, Yki-Järvinen H, Kantola I, Jula A, et al. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation. 1999;100:2425–2430
  73. de las Fuentes L, Herrero P, Peterson LR, Kelly DP, Gropler RJ, Dávila-Román VG. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension. 2003;41:83–87
  74. Nuutila P, Mäki M, Laine H, Knuuti MJ, Ruotsalainen U, Luotolahti M, et al. Insulin action on heart and skeletal muscle glucose uptake in essential hypertension. J Clin Invest. 1995;96:1003–1009
  75. Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res. 1999;42:246–253
  76. Lamb HJ, Beyerbacht HP, van der Laarse A, Stoel BC, Doornbos J, van der Wall EE, et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation. 1999;99:2261–2267
  77. Burkhard T, Herzog C, Linzbach S, Spyridopoulos I, Huebner F, Vogl TJ. Cardiac 31P-MRS compared to echocardiographic findings in patients with hypertensive heart disease without overt systolic dysfunction-preliminary results. Eur J Radiol. 2008;[Epub ahead of print]
  78. Stolen KQ, Kemppainen J, Kalliokoski KK, Hällsten K, Luotolahti M, Karanko H, et al. Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy. J Card Fail. 2004;10:132–140
  79. Weismüller S, Czernin J, Sun KT, Fung C, Phelps ME, Schelbert HR. Coronary vasodilatory capacity is impaired in patients with dilated cardiomyopathy. Am J Card Imaging. 1996;10:154–162
  80. Kronenberg MW, Cohen GI, Leonen MF, Mladsi TA, Di Carli MF. Myocardial oxidative metabolic supply-demand relationships in patients with nonischemic dilated cardiomyopathy. J Nucl Cardiol. 2006;13:544–553
  81. Tuunanen H, Engblom E, Naum A, Scheinin M, Någren K, Airaksinen J, et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail. 2006;12:644–652
  82. Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Non-invasive estimation of myocardial efficiency using positron emission tomography and carbon-11 acetate -comparison between the normal and failing human heart. Eur J Nucl Med. 2000;27:319–326
  83. Dávila-Román VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271–277
  84. Stolen KQ, Kemppainen J, Kalliokoski KK, Luotolahti M, Viljanen T, Nuutila P, et al. Exercise training improves insulin-stimulated myocardial glucose uptake in patients with dilated cardiomyopathy. J Nucl Cardiol. 2003;10:447–455
  85. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest. 1971;50:1386–1389
  86. Tuunanen H, Engblom E, Naum A, Någren K, Hesse B, Airaksinen KE, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 2006;114:2130–2137
  87. Walecki J, Michalak MJ, Michalak E, Bilinska ZT, Ruzyllo W. Usefulness of 1H MR spectroscopy in the evaluation of myocardial metabolism in patients with dilated idiopathic cardiomyopathy: pilot study. Acad Radiol. 2003;10:1187–1192
  88. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J. 1991;122:795–801
  89. Beer M, Seyfarth T, Sandstede J, Landschutz W, Lipke C, Kostler H, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267–1274
  90. Perseghin G, De Cobelli F, Esposito A, Belloni E, Lattuada G, Canu T, et al. Left ventricular function and energy metabolism in middle-aged men undergoing long-lasting sustained aerobic oxidative training. Heart. 2009;95:630–635
  91. Beer M, Wagner D, Myers J, Sandstede J, Köstler H, Hahn D, et al. Effects of exercise training on myocardial energy metabolism and ventricular function assessed by quantitative phosphorus-31 magnetic resonance spectroscopy and magnetic resonance imaging in dilated cardiomyopathy. J Am Coll Cardiol. 2008;51:1883–1891
  92. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118:1250–1258
  93. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27:942–948
  94. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280–3288
  95. Kankaanpää M, Lehto HR, Pärkkä JP, Komu M, Viljanen A, Ferrannini E, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab. 2006;91:4689–4695
  96. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47:51–58

PII: S0939-4753(09)00210-5

doi: 10.1016/j.numecd.2009.08.011

Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 3 , Pages 147-156 , March 2010

Article Tools

* Image Usage & Resolution